Cargando…
Open Targets Platform: supporting systematic drug–target identification and prioritisation
The Open Targets Platform (https://www.targetvalidation.org/) provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence. It is publicly available and the underlying code is open source...
Autores principales: | Ochoa, David, Hercules, Andrew, Carmona, Miguel, Suveges, Daniel, Gonzalez-Uriarte, Asier, Malangone, Cinzia, Miranda, Alfredo, Fumis, Luca, Carvalho-Silva, Denise, Spitzer, Michaela, Baker, Jarrod, Ferrer, Javier, Raies, Arwa, Razuvayevskaya, Olesya, Faulconbridge, Adam, Petsalaki, Eirini, Mutowo, Prudence, Machlitt-Northen, Sandra, Peat, Gareth, McAuley, Elaine, Ong, Chuang Kee, Mountjoy, Edward, Ghoussaini, Maya, Pierleoni, Andrea, Papa, Eliseo, Pignatelli, Miguel, Koscielny, Gautier, Karim, Mohd, Schwartzentruber, Jeremy, Hulcoop, David G, Dunham, Ian, McDonagh, Ellen M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779013/ https://www.ncbi.nlm.nih.gov/pubmed/33196847 http://dx.doi.org/10.1093/nar/gkaa1027 |
Ejemplares similares
-
Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics
por: Ghoussaini, Maya, et al.
Publicado: (2020) -
The next-generation Open Targets Platform: reimagined, redesigned, rebuilt
por: Ochoa, David, et al.
Publicado: (2022) -
Open Targets Platform: new developments and updates two years on
por: Carvalho-Silva, Denise, et al.
Publicado: (2019) -
An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci
por: Mountjoy, Edward, et al.
Publicado: (2021) -
Network expansion of genetic associations defines a pleiotropy map of human cell biology
por: Barrio-Hernandez, Inigo, et al.
Publicado: (2023)